38 /100
MEDIUM RISK
Score updated May 30, 2026

LCTX — Lineage Cell Therapeutics, Inc. Dilution Risk Tracker

Track LCTX dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track LCTX — Get alerts when the score changes →

📊 Score Breakdown

📋 Offering Ability
65
💰 Cash Runway
0
📊 Float Risk
27
⚠️ Warrant Exposure
50
🔄Convertible Debt

🌦️ Dilution Forecast

🌥️
Advisory
Moderate dilution signals present
37%
📉 Score Deterioration 40%
• Score rose 18 points recently (worsening)
💰 Capital Raise 38%
• Active shelf registration ($100M, 30% of market cap)
• Active ATM program with $37M remaining capacity
🔄 Reverse Split 30%
• 50-day avg $1.46 approaching $1 threshold
🔔 Track LCTX — Get forecast alerts →

💹 Market Data

Market Cap$331.57M
Shares Outstanding249.30M
Float187.28M
Cash$53.38M
Debt$2.39M
Short InterestN/A

🏛 Institutional Holdings

QoQ: ↑ 13.9% shares (2025Q4 vs prior)
123 institutional holders · 102.18M shares
#1 BROADWOOD CAPITAL INC 49.56M shares
#2 VANGUARD GROUP INC 9.64M shares
#3 Defender Capital, LLC. 6.83M shares
+ 17 more holders Sign up free to view →

📉 Short Interest

Short Interest25.92M
Days to Cover16.8
% of Float13.8%
FINRA data as of May 15, 2026

📁 Recent SEC Activity

xbrl XBRL WARRANT Mar 31, 2026
xbrl XBRL CONVERTIBLE Dec 31, 2017
EFFECT EFFECT Mar 23, 2026
4 INSIDER TRANSACTION Mar 12, 2026
S-3 SHELF Mar 11, 2026
Full SEC filing analysis available with free account

📰 Recent News

No recent news
Track LCTX Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking LCTX — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required
🔬 More Research for LCTX
📊 LCTX FDA Catalyst Timeline & Biotech Grade — BiotechSigns 📡 LCTX Signal Convergence & Dark Pool Activity — StonkWhisper

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.